Extracorporeal membrane oxygenation (ECMO) reconsidered

Area of Science:

• Critical Care Medicine
• Respiratory Medicine
• Medical Technology Evaluation

Background:

• The efficacy of extracorporeal membrane oxygenation (ECMO) for acute respiratory distress syndrome (ARDS) remains debated, despite recent trial publications.
• Bayesian meta-analytic methods are employed to synthesize evidence from randomized controlled trials (RCTs) on ECMO for ARDS.

Purpose of the Study:

• To estimate the treatment effect of ECMO on mortality in ARDS using Bayesian meta-analysis.
• To critically evaluate the methodological aspects and outcomes of the CESAR trial for ECMO in severe adult respiratory failure.
• To determine the optimal role of ECMO in ARDS management.

Main Methods:

• Bayesian meta-analysis of three randomized controlled trials (RCTs) involving ECMO for ARDS.
• Assessment of methodological challenges in pragmatic trials, including composite endpoints, sample size, treatment comparisons, and non-compliance.
• Evaluation of cost-effectiveness and cost-utility analyses.

Main Results:

• The estimated mortality odds ratio for ECMO in ARDS was 0.78 (95% credible interval, 0.25-3.04), with a 30% probability of a harmful effect (OR > 1).
• A null effect of ECMO is not excluded, indicating weak evidence of efficacy.
• The CESAR trial exhibited methodological concerns regarding clinical and economic outcomes.

Conclusions:

• Current evidence suggests weak efficacy for ECMO in ARDS, with a null effect not being excluded.
• Methodological limitations in the CESAR trial raise concerns about its clinical and economic findings.
• ECMO may be best utilized as a rescue therapy, and further RCTs are warranted to resolve current uncertainties.